ID

34411

Descripción

Non-interventional Study With Pomalidomide (Imnovid®); ODM derived from: https://clinicaltrials.gov/show/NCT02075996

Link

https://clinicaltrials.gov/show/NCT02075996

Palabras clave

  1. 17/1/19 17/1/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

17 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Multiple Myeloma NCT02075996

Eligibility Multiple Myeloma NCT02075996

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with relapsed or refractory multiple myeloma patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen
Descripción

ID.1

Tipo de datos

boolean

adult male and female patients (at least 18 years with no upper age limit)
Descripción

ID.2

Tipo de datos

boolean

written informed consent to data collection and pseudonymized data transfer
Descripción

ID.3

Tipo de datos

boolean

the conditions of the pregnancy prevention programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics imnovid®)
Descripción

ID.4

Tipo de datos

boolean

other criteria according to summary of product characteristics imnovid®
Descripción

ID.5

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
missing patient's informed consent
Descripción

ID.6

Tipo de datos

boolean

pregnant or breast-feeding women
Descripción

ID.7

Tipo de datos

boolean

male patients, not capable of complying the required preventive measures (see summary of product characteristics imnovid®)
Descripción

ID.8

Tipo de datos

boolean

other criteria according to summary of product characteristics imnovid®
Descripción

ID.9

Tipo de datos

boolean

Similar models

Eligibility Multiple Myeloma NCT02075996

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with relapsed or refractory multiple myeloma patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen
boolean
ID.2
Item
adult male and female patients (at least 18 years with no upper age limit)
boolean
ID.3
Item
written informed consent to data collection and pseudonymized data transfer
boolean
ID.4
Item
the conditions of the pregnancy prevention programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics imnovid®)
boolean
ID.5
Item
other criteria according to summary of product characteristics imnovid®
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
missing patient's informed consent
boolean
ID.7
Item
pregnant or breast-feeding women
boolean
ID.8
Item
male patients, not capable of complying the required preventive measures (see summary of product characteristics imnovid®)
boolean
ID.9
Item
other criteria according to summary of product characteristics imnovid®
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial